India Diabetes Market anticipated growing with 6.5% CAGR Due to the high number of patients between 2016 and 2023

India Diabetes Market information, by Type (Type 1, Type 2, and Gestational diabetes), by Test (Random blood sugar test, Fasting blood sugar test, Oral glucose tolerance test, Initial glucose challenge test and others), by Devices (Blood glucose monitoring devices, Diabetes management devices, and others) by Treatment (Medications, Insulin therapy, Transplantation, Bariatric surgery and others) – Forecast to 2023

The chronic metabolic ailment called diabetes causes high blood sugar, making human body incapable of producing insulin. World Health Organization (WHO) is also raised concern about the high percentage of Indian population suffering from diabetes. Apart from the high density of population and a large percentage of patients, the other factors that are driving diabetes market in India include developing healthcare infrastructure, increasing awareness, increasing spending on health care, increasing urbanization, and untouched rural market. Being a genetic disorder and due to the unhealthy lifestyle of many people, diabetes is rapidly increasing among people, leading to growth in demand for diabetes remedy and growth in its market.

Market Research Future (MRFR) has published a research report about the India diabetes services market that anticipates aggrandizement for this market with 6.5% CAGR (Compound Annual Growth Rate) between 2016 and 2023. In terms of cash, the market is expected to rise from US$ 4778.7 mn in 2016 to US$ 7441.6 mn by 2023. Along with the insights about factors affecting this market, this report analyzes the market on the basis of various factors in order to forecast the future growth potential. Featuring expert opinions about market structure, the report lists the profiles of key players in the market. Evaluating the competitive developments, this report covers joint ventures, mergers and acquisitions, new product developments, research and developments (R & D), and strategic alliances.

Get Sample Copy @

In this report, the India diabetes market has been segmented on the basis of devices, treatment, test, type, and lastly region. Based on devices, this market has been segmented into blood glucose monitoring devices, diabetes management devices, and others. Based on treatment, the market has been segmented into bariatric surgery, insulin therapy, medications, transplantation, and others. Transplantation involves a pancreas transplant that can cure diabetes and eliminate the need for insulin shots. Usually, known as weight loss surgery, bariatric surgery includes a variety of procedures performed on people who have obesity.

By types, the market segmentation of India diabetes market covers type 1, type 2, and gestational diabetes. Type 1 & 2 of diabetes harm the body in the same way. The difference between them is regarding insulin.

The regional segmentation of India diabetes market segments the market into regions namely Northern region, Central region Southern region, Eastern region and Western region. According to the report, the western region is believed to be the largest market for diabetes. This region includes Maharashtra whose capital Mumbai is regarded as the economic capital of India. Due to the high purchasing power of people, the market has a strong chance of growth here. Eastern and Northern regions are also growing, and during the forecast period, they are expected to jointly hold the position of the second largest market for India Diabetes. Southern Indian market is expected to grow at significantly in the India diabetes during the forecast period. The report predicts limited but moderate growth for the Central region market.

Apply for Exclusive Discount @

Key Players

The key players in India diabetes market include Bayer AG (Germany), Becton Dickinson and Company {United States of America (USA)}, Johnson & Johnson Services, Inc.(the USA), Merck & Co., Inc. (the USA), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Roche Diabetes Care, Inc.(the USA), Sanofi-aventis U.S. LLC (USA), USV Private Limited (India), and Ypsomed (Switzerland).

Latest Industry News

  • The medical fraternity of Hyderabad, Telangana, has decided to adopt new regimen for treating diabetes, glycemic pentad, with two more parameters added to the existing three will help make a proper assessment of the disease in an individual. The traditional management always targeted the triad of fasting plasma glucose, postprandial glucose, and HBA1c. However, now there are two other parameters that have to be examined which are glycemic variability and quality of life, all of them together are now known as glycemic pentad. 20 JUL 2018
  • The Swiss multinational pharmaceutical company Novartis has obtained court orders restraining five Ahmedabad-based pharma companies from manufacturing its patented drug for diabetes. 6 AUG 2018

Send An Enquiry @

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India